Consolidated Statements of Loss and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Research and development collaborations (note 12)	$ 26,680,000	$ 38,951,000	$ 29,544,000
Operating expenses:
Research and development	199,752,000	171,203,000	117,367,000
General and administrative	42,561,000	55,216,000	62,710,000
Impairment of acquired IPR&D (note 6)	0	0	768,000
Total operating expenses	242,313,000	226,419,000	180,845,000
Loss from operations	(215,633,000)	(187,468,000)	(151,301,000)
Other income (expense):
Interest income	1,965,000	5,697,000	5,877,000
Other income (expense), net (note 13)	1,309,000	1,648,000	(595,000)
Total other income (expense), net	3,274,000	7,345,000	5,282,000
Loss before income taxes	(212,359,000)	(180,123,000)	(146,019,000)
Income tax recovery (expense), net (note 14)	516,000	(429,000)	582,000
Net loss and comprehensive loss	$ (211,843,000)	$ (180,552,000)	$ (145,437,000)
Net loss per common share (note 4):
Basic (in dollars per share)	$ (4.11)	$ (3.58)	$ (3.83)
Diluted (in dollars per share)	$ (4.61)	$ (3.58)	$ (3.83)
Weighted-average common shares outstanding (note 4):
Basic (in shares)	51,553,869	50,382,497	38,022,014
Diluted (in shares)	52,131,596	50,382,497	38,022,014